AbbVie completes acquisition of Allergan
The move significantly expands and diversifies AbbVie’s revenue base
Read More
Tag: Allergan
US regulators permit AbbVie/Allergan merger
The closing of the acquisition remains subject to other customary closing conditions
Read More
AbbVie to buy Allergan in $63b mega-merger
The deal is the second huge merger this year, after January’s Bristol-Myers Squibb & Celgene deal.
Read More
Allergan files anti-CGRP migraine drug in the US
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Read More
Allergan’s rapastinel fails to hit key targets in depression trials
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Read More
Health Canada restricts Allergan’s Esmya
Health Canada has placed restrictions on Allergan’s uterine fibroid treatment Esmya, after discovering a possible link between its use and the risk of a rare but serious liver injury.
Read More
NICE issues final draft guidelines for Novartis’ Kymriah
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read More
Pfizer loses landmark second medical use patent case
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
Read More
Allergan to file ubrogepant for migraine early next year
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Read More
Green light for acne drug Seysara in the US
US regulators have approved Paratek’s Seysara for the treatment of acne in patients aged nine years or older.
Read More
FDA accepts Allergan’s Vraylar for review
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Read More
Allergan, Sosei suspend clinical development of dementia drug
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.
Read More
- Gobivaz approved across Europe as first Simponi biosimilar
- Poolbeg granted European patent for POLB 001
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
